Fourie B - Search Results

1

Characterization of Intracellular Activity of Antitubercular Constituents the Roots of Euclea natalensis.

Lall N, Meyer JJM, Wang Y, Bapela NB, van Rensburg CEJ, Fourie B, Franzblau SG. Lall N, et al. Among authors: fourie b. Pharm Biol. 2005;43(4):353-357. doi: 10.1080/13880200590951829. Pharm Biol. 2005. PMID: 28925832 Free article.

2

Bioactive compounds from Lippia javanica and Hoslundia opposita.

Mujovo SF, Hussein AA, Meyer JJ, Fourie B, Muthivhi T, Lall N. Mujovo SF, et al. Among authors: fourie b. Nat Prod Res. 2008;22(12):1047-54. doi: 10.1080/14786410802250037. Nat Prod Res. 2008. PMID: 18780245

3

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA; Gatifloxacin for TB (OFLOTUB) study team. Rustomjee R, et al. Among authors: fourie b. Int J Tuberc Lung Dis. 2008 Feb;12(2):128-38. Int J Tuberc Lung Dis. 2008. PMID: 18230244 Clinical Trial.

4

Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.

Cholo MC, Mothiba MT, Fourie B, Anderson R. Cholo MC, et al. Among authors: fourie b. J Antimicrob Chemother. 2017 Feb;72(2):338-353. doi: 10.1093/jac/dkw426. Epub 2016 Oct 20. J Antimicrob Chemother. 2017. PMID: 27798208 Review.

5

Trials of anti-tuberculosis treatment as a diagnostic tool in smear-negative tuberculosis are of questionable benefit.

Fourie B, Weyer K. Fourie B, et al. Int J Tuberc Lung Dis. 2000 Nov;4(11):997. Int J Tuberc Lung Dis. 2000. PMID: 11092709 No abstract available.

6

Effects of clofazimine on planktonic and biofilm growth of Mycobacterium tuberculosis and Mycobacterium smegmatis.

Mothiba MT, Anderson R, Fourie B, Germishuizen WA, Cholo MC. Mothiba MT, et al. Among authors: fourie b. J Glob Antimicrob Resist. 2015 Mar;3(1):13-18. doi: 10.1016/j.jgar.2014.12.001. Epub 2014 Dec 23. J Glob Antimicrob Resist. 2015. PMID: 27873644

7

The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM; Lancet Respiratory Medicine drug-resistant tuberculosis Commission group. Dheda K, et al. Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2. Lancet Respir Med. 2019. PMID: 31486393 Review.

8

Quality and stability of TB medicines: let the buyer beware!

Laing R, Vrakking H, Fourie B. Laing R, et al. Among authors: fourie b. Int J Tuberc Lung Dis. 2004 Sep;8(9):1043-4. Int J Tuberc Lung Dis. 2004. PMID: 15455587 No abstract available.

9

Consensus statement on diagnostic end points for infant tuberculosis vaccine trials.

Hatherill M, Verver S, Mahomed H; Taskforce on Clinical Research Issues, Stop TB Partnership Working Group on TB Vaccines. Hatherill M, et al. Clin Infect Dis. 2012 Feb 15;54(4):493-501. doi: 10.1093/cid/cir823. Epub 2011 Dec 5. Clin Infect Dis. 2012. PMID: 22144538

10

Dealing with HIV-associated tuberculosis at the community level.

Fourie B. Fourie B. Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S2. Int J Tuberc Lung Dis. 2003. PMID: 12971647 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters